Photodynamic therapy with verteporfin (Visudyne): Impact on ophthalmology and visual sciences

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 3, 2000, Pages 624-628

  Bressler, Neil M ^a   Bressler, Susan B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; FUNDUS OCULI; HUMANS; MACULAR DEGENERATION; OPHTHALMOLOGY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS; VISION DISORDERS;

EID: 0034096740     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration: one year results of two randomized clinical trials - TAP Report #1. Arch Ophthalmol. 1999;117:1329-1345.
2. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 192; 99:933-943.
3. Vingerling JR, Dielemans I, Hofma A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
4. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from clinical trials. Arch Ophthalmol. 1993;111: 1200-1209.
5. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112:480-488.
6. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol. 1987;105: 209-213.
7. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993; 115:786-791.
8. Aveline B, Hasan T, Redmond RW. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol. 1994;59:328-335.
9. Manyak MJ, Russo A, Smith PD, Glatstein E. Photodynamic therapy. J Clin Oncol. 1988;6:380-391.
10. Roberts WG, Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res. 1992;52:924-930.
11. Zhou C. Mechanisms of tumor necrosis induced by photodynamic therapy. J Photochem Photobiol B. 1989;3:299-318.
12. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953-1961.
13. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
14. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D, Levy JG. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B. 1990;5:231-244.
15. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
16. Husain D, Miller JW, Michaud N, et al. Intravenous infusion using liposomal BPD for photodynamic therapy. Arch Ophthalmol. 1996;114:978-985.
17. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase I and II study. Arch Ophthalmol. 1999;117:1161-1173.
18. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy of choroidal neovascularization due to age-related macular degeneration using verteporfin: results of retreatments in a phase I and II study. Arch Ophthalmol. 1999;117:1177-1187.
19. Sickenberg M, Schimdt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome and idiopathic causes. Arch Ophthalmol. 2000;118. In press.
20. Thomas EL, Rosen R, Murphy R, Puliafito C, Jonsson P. Visual acuity stabilizes after a single treatment with SnET2-photodynamic therapy in patients with subfoveal choroidal neovascularization [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S401. Abstract nr 2112.
21. Arbour JD, Connolly EJ, Graham K, et al. Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S401. Abstract nr 2111.
22. Mones J, VIP Research Study Group. Photodynamic therapy (PDT) with verteporfin of subfoveal choroidal neovascularization in age-related macular degeneration: study design and baseline characteristics in the VIP randomized clinical trial [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S321. Abstract nr 1704.
23. Slakter J, VIP Research Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: study design and baseline characteristics in the VIP randomized clinical trial [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S401. Abstract nr 2114.